Mouallif S - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Page 1

Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.

Bhan V, Clift F, Baharnoori M, Thomas K, Patel BP, Blanchette F, Adlard N, Vudumula U, Gudala K, Dutta N, Grima D, Mouallif S, Farhane F. Bhan V, et al. Among authors: mouallif s. J Comp Eff Res. 2023 Sep;12(9):e220175. doi: 10.57264/cer-2022-0175. Epub 2023 Aug 22. J Comp Eff Res. 2023. PMID: 37606897 Free PMC article.

Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada.

Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, Cooney P, Blanchette F, Patel BP, Grima D. Baharnoori M, et al. Among authors: mouallif s. Pharmacoecon Open. 2022 Nov;6(6):859-870. doi: 10.1007/s41669-022-00363-1. Epub 2022 Sep 15. Pharmacoecon Open. 2022. PMID: 36107307 Free PMC article.

A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.

Duquette P, Yeung M, Mouallif S, Nakhaipour HR, Haddad P, Schecter R. Duquette P, et al. Among authors: mouallif s. PLoS One. 2019 Jan 14;14(1):e0210417. doi: 10.1371/journal.pone.0210417. eCollection 2019. PLoS One. 2019. PMID: 30640935 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Search Page

Filters